Evaluating multi-criteria decision-making in health technology assessment

Kelley, Leah; Egan, Rylan; Stockley, Denise; Johnson, Ana

doi:10.1016/j.hlpt.2018.05.002

Cited by 8 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even though in recent years there has been an increasing understanding of the need to seek a broader approach by considering additional parameters of bene t to the traditional ones (i.e., clinical and/or economic), only few publications assessed organizational requirements and/or human factors, which were reduced to usability and/or acceptability excluding a considerable contribution to the assessment in terms of human e cacy and effectiveness (19,(147)(148)(149)(150).…”

Section: Discussionmentioning

confidence: 99%

A systematic literature review of Real-World Evidence (RWE) on post-market assessment of medical devices

Manetti

Guidotti

Vola

et al. 2023

Preprint

View full text Add to dashboard Cite

The increasing use of real-world evidence (RWE) and real-world data (RWD) to assess post-market Medical Devices (MDs) might satisfy the urgent need for data sharing and traceability. This study sought to i) get an overview of current practice in post-market assessments of MDs reporting on RWE/RWD; ii) draw policy recommendations for governments and health organizations and identify a research agenda for scholars. A systematic review was undertaken until July 2020 following the PRISMA guidelines. Original peer-reviewed articles in English and incorporating RWE/RWD into any sort of post-market assessment strategy for an MD were included and their reference lists manually checked. A narrative synthesis was employed to describe evidence retrieved. Totally, 103 research articles were identified. Administrative databases were mostly utilised; clinical and/or economic evidence gathered in a short/medium time horizon the most frequently reported; other evidence types (e.g., organizational) underreported; patient perspectives rarely incorporated; the innovation complexity of MDs relatively low. To our knowledge, this study is the first in its kind to provide a comprehensive picture of how non-randomized evidence has been used when assessing MDs working in real-life conditions. The implications of this review might help policy-makers to better understand the risks and benefits of medium and long-term use of MDs alongside clinical practice and make more informed decisions about adoption and use.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic literature review of Real-World Evidence (RWE) on post-market assessment of medical devices

Manetti

Guidotti

Vola

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…A remote sensor is set in conditions that are essential to make the remote sensor environment. Since IoT gives ongoing information, it will permit better understanding and knowledge of infection advancement and the impacts of medication treatment [20].…”

Section: Application Of the Suggested Frameworkmentioning

confidence: 99%

“…At the point when the assurance is done, the interface will select such ailment and illustration the associated division that the patient can guidance to for extra amplification and test. We present MCDM (Multi Rules Decision Making) informative dynamic framework measure (AHP) that is a technique with hierarchal building for decision-making issues [19,20] to decide and foresee the illnesses of older individuals dependent on various side effects endured by them. MCDM AHP causes the client to comprehend the suitable assessment of their ailments which would along these lines order anticipation through conventional methodologies.…”

Section: Symptoms Checkermentioning

confidence: 99%

A Smart Health Monitoring Application for Patients to Improve Health

Ariza-Colpas

Butt

Tariq

et al. 2022

Advances in Information, Communication and Cybersecurity

View full text Add to dashboard Cite

Health is growing nowadays due to technological revolutions. These revolutions make health smart and easy to monitor the patient at their location. In this paper, we are suggesting and developing the smart health monitoring scenario. In our system, we are monitoring patients with the disease of frequent urine due to diabetes, stiffness of bones due to ortho disease, and heart rate monitoring due to heart disease we used some statically measured to find results from the generated data during the monitoring. Our system reveals that the scenario we created for monitoring patients at their location is more accurate and valuable during the decision-making to take appropriate action. Objective of this study is to support the elder patients for their remote health monitoring with the trustworthy scenario. We used an app development method for it. We used almost 10 patients to evaluate the results of our developed system. The study reveals that our developed system is very valuable for elder patients' health monitoring. We selected 10 patients with the mentioned diseases to monitor them and check the validity of our developed system. We find that our developed system is very efficient and useful for monitoring and generating an alarm in the case of any abnormality situations. In conclusion, there is an essential need for such systems that monitor the patient effectively and take decisions timely. In this paper, we implemented a model for elder patients to monitor the patient with different diseases such as frequent urine sugar levels, and stiffness in bones. For this, we deployed sensors in the patient's body and attached them to the mobile to transmit the data to the other ends. We also set an alarming stage in the system when there is any abnormality condition observed. The study reveals that there is a need for a more precise and decision support mechanism for disease monitoring to enhance the elder people life.

show abstract

“…This is not straightforward given there are no firm criteria for defining "better decision making" for drug reimbursement decisions. Nevertheless, key indicators of effectiveness for this particular case study could be whether in the long term the approach (i) enables better quality rationale for drug-listing recommendations, (ii) is used to address the affordability issues faced by the Ministry of Health (e.g., via disinvestment decisions), and (iii) remains in use by successive committees and for the latter, the recent evaluation of MCDA in improving consistency and transparency in non-drug HTA will be useful (36). In the short term, further reflections from the committee members on the use and acceptability of the process is needed and will further promote shared learning among drug reimbursement communities.…”

Section: Future Plansmentioning

confidence: 99%

Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience

Laba

Jiwani

Crossland³

et al. 2020

Int J Technol Assess Health Care

View full text Add to dashboard Cite

Objective To describe the implementation of multi-criteria decision analysis (MCDA) into a Canadian public drug reimbursement decision-making process, identifying the aspects of the MCDA approach, and the context that promoted uptake. Methods Narrative summary of case study describing the how, when, and why of implementing MCDA. Results Faced with a fixed budget, a pipeline of expensive but potentially valuable drugs, and potential delays to drug decision making, the Ministry of Health (i.e., decision makers) and its independent expert advisory committee (IAB) sought alternative values-based decision processes. MCDA was considered highly compatible with current processes, but the ability as a stand-alone intervention to address issues of opportunity cost was unclear. The IAB nevertheless collaboratively voted to implement an externally developed MCDA with support from decision makers. After several months of engagement and piloting, implementation was rapid and leveraged strong pre-existing formal and informal communication networks. The IAB as a whole rates new submissions which serves as an input into the deliberative process. Conclusions MCDA can be a highly adaptable approach that can be implemented into a functioning drug reimbursement setting when facilitated by (i) a truly limited budget; (ii) a shared vision for change by end-users and decision makers; (iii) using pre-existing deliberative processes; and (iv) viewing the approach as a decision framework rather than the decision (when appropriate). Given the current limitations of MCDA, implementing an academically imperfect tool first and evaluating later reflects a practical solution to real-time fiscal constraints and impending delays to drug approvals that may be faced by decision makers.

show abstract

Evaluating multi-criteria decision-making in health technology assessment

Cited by 8 publications

References 28 publications

A systematic literature review of Real-World Evidence (RWE) on post-market assessment of medical devices

A systematic literature review of Real-World Evidence (RWE) on post-market assessment of medical devices

A Smart Health Monitoring Application for Patients to Improve Health

Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience

Contact Info

Product

Resources

About